A Phase 1b Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (P13K/mTOR Inhibitor) In Combination With Other Anti-Tumor Agents

Trial Profile

A Phase 1b Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (P13K/mTOR Inhibitor) In Combination With Other Anti-Tumor Agents

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Gedatolisib (Primary) ; Cisplatin; Dacomitinib; Docetaxel
  • Indications Advanced breast cancer; Breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Aug 2017 Planned End Date changed from 1 Dec 2019 to 18 Dec 2019.
    • 17 Aug 2017 Planned primary completion date changed from 1 Dec 2019 to 18 Dec 2019.
    • 24 Jul 2017 Planned End Date changed from 29 Nov 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top